The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke (CAMAROS)
The CAMAROS Trial: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Sponsor: Dalhousie University
Listed as NCT04789616, this PHASE2 trial focuses on Stroke and remains actively recruiting participants. Sponsored by Dalhousie University, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Jan 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dalhousie University
- Memorial University of Newfoundland
- Parkwood Hospital, London, Ontario
- Riverview Health Centre Foundation
- Sunnybrook Health Sciences Centre
- The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- University Health Network, Toronto
- University of British Columbia
- University of Calgary
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .